BDAZ, thanks as always for the valuable posts.

As a non science person this research sounds like RVX with apabetalone might be barking up at least one tree that could lead to positive results - the anti-inflammatory characteristics of apabetalone. Plus apabetalone has 5 other impacts as I recall (complement, coagulation, etc).

Also, it appears that the target population for canakinumab is quite different from that of apabetalone. I am some what reassured by the specifity of the patient population of the BoM trial - patients with diabetes, CVD, low HDL. This specificity should optimize the chances of success (hopefully).

As I have stated in the past it would be great if we could receive some scientific feedback from these conferences but we never have.

GLTA

Toinv